%0 Journal Article %T Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. %A Miller JL %A Gevers E %A Bridges N %A Yanovski JA %A Salehi P %A Obrynba KS %A Felner EI %A Bird LM %A Shoemaker AH %A Angulo M %A Butler MG %A Stevenson D %A Goldstone AP %A Wilding J %A Lah M %A Shaikh MG %A Littlejohn E %A Abuzzahab MJ %A Fleischman A %A Hirano P %A Yen K %A Cowen NM %A Bhatnagar A %A %J Obesity (Silver Spring) %V 32 %N 2 %D 2024 02 2 %M 37919617 %F 9.298 %R 10.1002/oby.23928 %X This study assessed the effect of 1-year administration of diazoxide choline extended-release tablet (DCCR) on hyperphagia and other complications of Prader-Willi syndrome (PWS).
The authors studied 125 participants with PWS, age ≥ 4 years, who were enrolled in the DESTINY PWS Phase 3 study and who received DCCR for up to 52 weeks in DESTINY PWS and/or its open-label extension. The primary efficacy endpoint was Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score. Other endpoints included behavioral assessments, body composition, hormonal measures, and safety.
DCCR administration resulted in significant improvements in HQ-CT (mean [SE] -9.9 [0.77], p < 0.0001) and greater improvements in those with more severe baseline hyperphagia (HQ-CT > 22). Improvements were seen in aggression, anxiety, and compulsivity (all p < 0.0001). There were reductions in leptin, insulin, and insulin resistance, as well as a significant increase in adiponectin (all p < 0.004). Lean body mass was increased (p < 0.0001). Disease severity was reduced as assessed by clinician and caregiver (both p < 0.0001). Common treatment-emergent adverse events included hypertrichosis, peripheral edema, and hyperglycemia. Adverse events infrequently resulted in discontinuation (7.2%).
DCCR administration to people with PWS was well tolerated and associated with broad-ranging improvements in the syndrome. Sustained administration of DCCR has the potential to reduce disease severity and the burden of care for families.